Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Gleibner E, Muhlbacher A, Kieseier B. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Ther Adv Neurol Disord. 2016 Mar;9(2):95-104. doi: 10.1177/1756285615622736.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Lee E, Candrilli SD, Roberts CS, Tang SSK, Bassin S, Wong ND. Regional Differences in the Prevalence, Treatment and Control of Hypertension and Dyslipidemia in Us Urban Hispanic Populations Participating in Health Screening Events. Ethn Dis. 2008 Sep 1;18(4):409-14.
Quandt SA, Graham CN, Bell RA, Snively BM, Golden SL, Stafford JM, Arcury TA. Ethnic disparities in health-related quality of life among older rural adults with diabetes. Ethn Dis. 2007;17(3):471-6.